A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomitantly With Omeprazole 80 mg/Day in Healthy Male and Female Subjects.

Trial Profile

A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomitantly With Omeprazole 80 mg/Day in Healthy Male and Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2011

At a glance

  • Drugs Clopidogrel; Omeprazole
  • Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Cardiovascular disorders; Duodenal ulcer; Dyspepsia; Embolism and thrombosis; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; Ischaemic heart disorders; Myocardial infarction; Peptic ulcer; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris; Zollinger-Ellison syndrome
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 25 Aug 2010 Trial phase changed from IV to I as reported by ClinicalTrials.gov.
    • 29 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top